Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From Breast Cancer Candidate

  • Ambrx Biopharma Inc AMAM announced preliminary safety and efficacy data from its Phase 2 ACE‑Breast-03 study. 
  • The data presented demonstrated a 51.7% overall response rate (ORR) and 100% disease control rate (DCR) after treatment with ARX788 in HER2-positive mBC patients who are resistant or refractory to T-DM1.
  • ACE-Breast-03 is a Phase 2 study of ARX788 for patients whose metastatic disease is resistant or refractory to T-DXd, T-DM1, or tucatinib-containing regimens. 
  • Related: Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason.
  • Patients had a median time on therapy of 7.2 months, and treatment remains ongoing. 
  • None of the patients experienced drug-related serious adverse events (SAEs), and all adverse events (AEs) were well tolerated, with no treatment discontinuations from AEs.
  • Two Phase 3 studies and one registration-enabled Phase 2 study with ARX788 conducted by Amrbrx's partner, NovoCodex Biopharmaceuticals, are ongoing in China, with projected readouts in 2023.
  • Price Action: AMAM shares are up 180.6% at $1.15 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!